The clinical landscape of HIF2α inhibitors in oncology
E
Eddy Saad
M
Marc Machaalani
D
David F. McDermott
(Division of Medical Oncology, Department of Medicine Beth Israel Deaconess Medical Center Boston Massachusetts USA)
T
Toni K. Choueiri
(Department of Medical Oncology Dana‐Farber Cancer Institute Boston Massachusetts USA)
Article Details
Journal
Nature Reviews Clinical Oncology
Volume / Issue
Vol. 23, Issue 7
Published
July 01, 2026
Pages
501-519
ISSN
1759-4774
Publisher
Springer Science and Business Media LLC
Journal Info
Nature Reviews Clinical Oncology
Springer Science and Business Media LLC
ISSN: 1759-4774 Q1 Medicine
Authors (4)
E
Eddy Saad
M
Marc Machaalani
D
David F. McDermott
Division of Medical Oncology, Department of Medicine Beth Israel Deaconess Medical Center Boston Massachusetts USA
T
Toni K. Choueiri
Department of Medical Oncology Dana‐Farber Cancer Institute Boston Massachusetts USA
Related Articles from this Journal
Ibrutinib improves overall survival in patients with mantle cell lymphoma
Peter Sidaway
Jul 2026
10.1038/s41571-026-01166-7
First-line zanidatamab–chemotherapy with or without tislelizumab improves survival in advanced-stage HER2+ GEA
Diana Romero
Jul 2026
10.1038/s41571-026-01169-4
Clinical implementation of multi-cancer early detection tests: can we find a path forward?
Ariadna Tibau, Aaron S. Kesselheim
Jul 2026
10.1038/s41571-026-01158-7
Pan-RAS inhibitor daraxonrasib shows promise in pancreatic cancer
David Killock
Jul 2026
10.1038/s41571-026-01162-x
Liquid biopsy to inform adjuvant decisions during neoadjuvant chemotherapy — a full-circle moment for nasopharyngeal cancer
W. K. Jacky Lam, Brigette B. Y. Ma
Jul 2026
10.1038/s41571-026-01157-8